Final NICE no for Shire’s pancreatic cancer drug
Pancreatic cancer patients will not be able to get routine access to Shire’s Onivyde on the National Health Service following a final rejection from cost regulators
Read More
Tag: irinotecan
NICE rejects Shire’s pancreatic cancer drug
Shire’s Onivyde has been turned down by the National Institute for Health and Care Excellence as an NHS-funded treatment for pancreatic cancer.
Read More
EU green light for Shire’s pancreatic cancer drug Onivyde
The European Medicines Agency has now issued a green light for Shire’s pancreatic therapy Onivyde, following its US approval in July this year.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
